In this study, hyperbaric oxygen therapy (HBOT) is proposed as a possible in vivo angiogenic stimulator for improving microvascular myocardial perfusion. Surprisingly, HBOT has not been extensively evaluated in patients with chronic stable ischemic heart disease and to date, its evaluation in cardiovascular diseases was primarily in the context of acute coronary syndrome, amelioration of ischemic-reperfusion injury and stem cell research.